SCHEMBL3479560

SCHEMBL3479560

CN(C)S(=O)(=O)c1ccc(-c2ccc(F)cc2N2C(=O)NC(=O)C23CCN(Cc2ccccc2)CC3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.43
NR1H2 P55055 1/20 0.41
BACE1 P56817 3/20 0.40
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
CXCR4 P61073 2/20 0.39
MLNR O43193 1/20 0.38
JAK2 O60674 3/20 0.38
JAK1 P23458 3/20 0.38
DRD2 P14416 2/20 0.38
SIGMAR1 Q99720 2/20 0.38
ADORA2B P29275 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
CCR5 P51681 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3479647 0.94 MCHR1 (0.39) MCHR1NR1H2BACE1ALDH1A1TSHR
SCHEMBL3479554 0.88 JAK2 (0.37) MCHR1NR1H2BACE1JAK2JAK1
Trifluoroacetic Acid SCHEMBL3479427 0.85 NR1H2 (0.35) MCHR1NR1H2BACE1ALDH1A1TSHR
SCHEMBL13031015 0.80 JAK2 (0.36) NR1H2BACE1ALDH1A1MLNRJAK2
SCHEMBL13031022 0.80 BACE1 (0.39) NR1H2BACE1ALDH1A1TSHRCXCR4
SCHEMBL3479561 0.78 BACE1 (0.37) MCHR1BACE1JAK2JAK1DRD2
SCHEMBL3479461 0.78 BACE1 (0.40) BACE1SIGMAR1
SCHEMBL3479460 0.78 BACE1 (0.40) BACE1SIGMAR1
SCHEMBL594258 0.76 PTGS2 (0.40) DRD2SIGMAR1
SCHEMBL3479470 0.76 JAK2 (0.35) MCHR1NR1H2BACE1JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US claimed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease BACE1, APP, PSEN1 MCHR1 4417/4885NR1H2 64/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.